Does Skinvive Need Repeating Every Six Months?

Skinvive’s six-month results are not a prescription to repeat treatment every six months. We distinguish the duration of improvement observed in a study from the right timing for an individual’s next treatment. The study schedule alone cannot determine that date.

What did the six-month result measure?

The U.S. Food and Drug Administration’s 2023 approval materials address improvement in cheek skin smoothness in adults age 21 and older. According to the FDA’s patient information, improvement lasted six months for most participants in the clinical study.

That does not guarantee the same duration for everyone. It also should not be extended to claims about other treatment areas or the scope of approval in South Korea.

An initial touch-up is different from maintenance

The same FDA patient information states that the study allowed a touch-up one month after the initial treatment, and 73% of treated participants received one. Describing the result as “one treatment lasts six months for everyone” leaves out an important study condition.

The patient information distinguishes two purposes:

• Touch-up treatment: a small additional injection to help achieve the desired result after the initial treatment.
• Repeat treatment: an injection to maintain the result after the initial effect has diminished.

The study offered an opportunity for repeat treatment after six months. That was part of the study design, not a treatment schedule prescribed for everyone.

What should you discuss before repeat treatment?

Before discussing another treatment, gather the details of your previous treatment and any changes you have noticed:

• When you had the initial treatment and whether you had a touch-up.
• How the effect seems to have changed.
• Whether any discomfort or other symptoms remain.

Discuss these points with your treating clinician. The decision should take your current skin condition and treatment goals into account, rather than relying on the calendar alone.

When symptoms need attention first

The FDA’s patient information advises contacting your clinician if redness or visible swelling lasts more than a few days, or if an adverse reaction develops weeks or months later. In these situations, symptom assessment comes before planning another treatment.

The same information says to notify a medical professional immediately about vision changes, skin turning white, unusual pain during or shortly after treatment, or signs of a stroke, such as sudden difficulty speaking or weakness in an arm or leg.

Our takeaway: use the six-month finding to understand the study, not to set an automatic appointment. Before repeating Skinvive, discuss the previous treatment, the changes you notice, and any unresolved symptoms with your treating clinician.